Kang, Narae Oh, Hyun Jeong Hong, Ji Hey Moon, Hyo Eun Kim, Yona 이현정 Min, Ho phil Park, Hyeonji Lee, Sang Hun Paek, Sun Ha Jin, Jonghwa 2024-01-12T06:33:26Z 2024-01-12T06:33:26Z 2023-10-27 2023-10 1542-6416 https://pubs.kist.re.kr/handle/201004/79798 Glioblastoma is one of the most malignant primary brain cancer. Despite surgical resection with modern technology followed by chemo-radiation therapy with temozolomide, resistance to the treatment and recurrence is common due to its aggressive and infiltrating nature of the tumor with high proliferation index. The median survival time of the patients with glioblastomas is less than 15 months. Till now there has been no report of molecular target specific for glioblastomas. Early diagnosis and development of molecular target specific for glioblastomas are essential for longer survival of the patients with glioblastomas. Development of biomarkers specific for glioblastomas is most important for early diagnosis, estimation of the prognosis, and molecular target therapy of glioblastomas. To that end, in this study, we have conducted a comprehensive proteome study using primary cells and tissues from patients with glioblastoma. In the discovery stage, we have identified 7429 glioblastoma-specific proteins, where 476 proteins were quantitated using Tandem Mass Tag (TMT) method; 228 and 248 proteins showed up and down-regulated pattern, respectively. In the validation stage (20 selected target proteins), we developed quantitative targeted method (MRM: Multiple reaction monitoring) using stable isotope standards (SIS) peptide. In this study, five proteins (CCT3, PCMT1, TKT, TOMM34, UBA1) showed the significantly different protein levels (t-test: p value？≤？0.05, AUC？≥？0.7) between control and cancer groups and the result of multiplex assay using logistic regression showed the 5-marker panel showed better sensitivity (0.80 and 0.90), specificity (0.92 and 1.00), error rate (10 and 2%), and AUC value (0.94 and 0.98) than the best single marker (TOMM34) in primary cells and tissues, respectively. Although we acknowledge that the model requires further validation in a large sample size, the 5 protein marker panel can be used as baseline data for the discovery of novel biomarkers of the glioblastoma. English Humana Press, Inc. Glial cell proteome using targeted quantitative methods for potential multi-diagnostic biomarkers Article 10.1186/s12014-023-09432-x 1 Clinical Proteomics, v.20, no.1 Clinical Proteomics 20 1 Y scie scopus 001086758900001 Biochemical Research Methods Biochemistry & Molecular Biology Article RADIOTHERAPY PLUS CONCOMITANT GLIOBLASTOMA PATTERNS FAILURE CLASSIFICATION TEMOZOLOMIDE RADIATION OUTCOMES HEALTH MRM Glioblastoma Primary cell Biomarker Quantitative proteomics